Posts

Otsuka's $1.225B Acquisition of Transcend Therapeutics for PTSD Neuroplastogen TSND-201

on

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

on

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

on

FDA Rejects Lundbeck and Otsuka's Rexulti for PTSD on Insufficient Efficacy Evidence

on

FDA Advisory Committee Rejects Lundbeck and Otsuka's PTSD Bid for Rexulti

on

Transcend's neuroplastogen posts positive mid-stage results in PTSD

on